PROCEPT BioRobotics Corporation (PRCT) is a Medical - Devices company in the Healthcare sector, currently trading at $24.59. It has a SharesGrow Score of 54/100, indicating a mixed investment profile with 3 out of 7 criteria passed.
Analyst consensus target is PRCT = $47 (+91.1% upside).
Valuation: PRCT trades at a trailing Price-to-Earnings (P/E) of -13.9 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.35.
Financials: revenue is $308M, +61.2%/yr average growth. Net income is $96M (loss), growing at -1.3%/yr. Net profit margin is -31% (negative). Gross margin is 63.7% (+14.3 pp trend).
Balance sheet: total debt is $52M against $366M equity (Debt-to-Equity (D/E) ratio 0.14, conservative). Current ratio is 6.85 (strong liquidity). Debt-to-assets is 10.2%. Total assets: $508M.
Analyst outlook: 11 / 15 analysts rate PRCT as buy (73%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 91/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 67/100 (Partial), Moat 70/100 (Pass), Future 85/100 (Pass), Income 10/100 (Fail).
